SBIA
NVCR icon

Sheaff Brock Investment Advisors’s NovoCure NVCR Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-950
Closed -$210K – 563
2021
Q2 		$210K Buy
+950
New +$185K 0.02% 462

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sheaff Brock Investment Advisors's NVCR Position: Q3 2021 in Review

Sheaff Brock Investment Advisors sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 950 shares — an estimated $210K sold.

Sheaff Brock Investment Advisors first reported a position in NVCR in Q2 2021 and held it in 1 quarter. The position peaked at $210K in Q2 2021. 317 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

  • Sheaff Brock Investment Advisors reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
  • Sheaff Brock Investment Advisors sold 950 NovoCure shares in Q3 2021, an estimated $210K.
  • Sheaff Brock Investment Advisors first reported a position in NovoCure in Q2 2021 and held it in 1 quarter.
  • Sheaff Brock Investment Advisors's NovoCure position peaked at $210K in Q2 2021.
  • 317 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on Sheaff Brock Investment Advisors's 13F filing for Q3 2021, filed 3 Nov 2021.